抗生素的过去现在与将来（英文PPT）AntibioticsPast Present and .pptVIP

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Health Professionals Can Impact Other clinicians Patients Optimize patient evaluation Adopt judicious antibiotic prescribing practices Vaccinate patients Optimize consultations with other clinicians Use infection control measures Educate others about judicious use of antibiotics Conclusion * * * * * * * * * * * * * * * * * * * * It’s important to remember humans did not invent antimicrobials, we just discovered them. * * * * * * * * * * 5-Year E coli % Resistance Trend from TRUST 2003 to 2007 In vitro activity does not necessarily correlate with clinical results. Data on file, Ortho-McNeil-Janssen Pharmaceuticals, Inc. Antimicrobial Agent 2003 N=915 2004 N=760 2005 N=1303 2006 N=1435 2007 N=1724 5-year % Incr Ampicillin Trimeth/sulfa Ciprofloxacin Levofloxacin Gentamicin 34.6 16.8 9.1 9.1 4.0 39.7 19.3 9.5 9.5 4.9 41.0 19.5 9.8 9.4 4.9 44.7 20.4 14.8 14.0 6.8 48.3 26.3 19.6 18.9 7.9 13.7 9.5 10.5 9.8 3.9 Ciprofloxacin Levofloxacin GU Scripts Source: SDI/ IMS Total GU TRxs ciprofloxacin 2005-2007 incr of 33% (1.3M scripts) Introduction of generic ciprofloxacin So How Do We Combat Resistance? New Antibiotic Development Appropriate Antibiotic Usage New Drug Research and Development An Aggressive RD Program Initiated Today Would Likely Require 10 or More Years and an Investment of $800 Million to $1.7 Billion to Bring a New Drug to Market. [9] [9]Copyright IDSA 2007, info@ Molecule to Medicine mms:///Project/LR/2007/JJPRD/PRD0002T0531WegMolec_E.wmv I Wanna New Drug!!!!! Challenges for Antibiotic Research and Development Because antibiotics work so well and so fast, in most cases they simply don’t have as large a market as drugs that treat chronic, long-term conditions or lifestyle issues. [10] The development of resistant strains of bacteria limits the long-term potential for an antibiotic. [10] [10] Copyright IDSA 2007, info@ Challenges Continued Infectious disease experts often